Ardelyx Tops Estimates as Sales Surge

Ardelyx (NASDAQ:ARDX), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release highlighted considerable progress in the company's commercialization of its two approved drugs, Ibsrela and Xphozah. The company reported earnings per share (EPS) of $0.02, higher than the analysts' consensus estimate of $0.01. Revenue of $116.1 million exceeded the expected $111 million. Source: Analysts' estimates for the quarter provided by FactSet.Ardelyx develops treatments for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia, a condition often found in chronic kidney disease patients who are on dialysis. Its products, Ibsrela and Xphozah, cater to significant medical needs that were previously unmet, offering unique mechanisms of action.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool